Cellectar biosciences highlights promising interim data from its ongoing study of iopofosine i 131 in multiple myeloma in an oral presentation at the snmmi annual meeting

Interim data from 64 refractory multiple myeloma patients demonstrated an orr of 28%, a cbr of 70%, and a dcr of 92%

CLRB Ratings Summary

CLRB Quant Ranking